487 related articles for article (PubMed ID: 25728526)
1. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.
Melichar B; Adenis A; Lockhart AC; Bennouna J; Dees EC; Kayaleh O; Obermannova R; DeMichele A; Zatloukal P; Zhang B; Ullmann CD; Schusterbauer C
Lancet Oncol; 2015 Apr; 16(4):395-405. PubMed ID: 25728526
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
3. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
Niu H; Shin H; Gao F; Zhang J; Bahamon B; Danaee H; Melichar B; Schilder RJ; Coleman RL; Falchook G; Adenis A; Behbakht K; DeMichele A; Dees EC; Perez K; Matulonis U; Sawrycki P; Huebner D; Ecsedy J
EBioMedicine; 2017 Nov; 25():50-57. PubMed ID: 29122619
[TBL] [Abstract][Full Text] [Related]
4. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Falchook G; Coleman RL; Roszak A; Behbakht K; Matulonis U; Ray-Coquard I; Sawrycki P; Duska LR; Tew W; Ghamande S; Lesoin A; Schwartz PE; Buscema J; Fabbro M; Lortholary A; Goff B; Kurzrock R; Martin LP; Gray HJ; Fu S; Sheldon-Waniga E; Lin HM; Venkatakrishnan K; Zhou X; Leonard EJ; Schilder RJ
JAMA Oncol; 2019 Jan; 5(1):e183773. PubMed ID: 30347019
[TBL] [Abstract][Full Text] [Related]
5. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
[TBL] [Abstract][Full Text] [Related]
7. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.
Brunner AM; Blonquist TM; DeAngelo DJ; McMasters M; Fell G; Hermance NM; Winer ES; Lindsley RC; Hobbs GS; Amrein PC; Hock HR; Steensma DP; Garcia JS; Luskin MR; Stone RM; Ballen KK; Rosenblatt J; Avigan D; Nahas MR; Mendez LM; McAfee SL; Moran JA; Bergeron M; Foster J; Bertoli C; Manning AL; McGregor KL; Fishman KM; Kuo FC; Baltay MT; Macrae M; Burke M; Behnan T; Wey MC; Som TT; Ramos AY; Rae J; Lombardi Story J; Nelson N; Logan E; Connolly C; Neuberg DS; Chen YB; Graubert TA; Fathi AT
Lancet Haematol; 2020 Feb; 7(2):e122-e133. PubMed ID: 31837959
[TBL] [Abstract][Full Text] [Related]
8. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.
Kudo T; Hamamoto Y; Kato K; Ura T; Kojima T; Tsushima T; Hironaka S; Hara H; Satoh T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Doki Y; Kitagawa Y
Lancet Oncol; 2017 May; 18(5):631-639. PubMed ID: 28314688
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
11. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
12. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
Dickson MA; Mahoney MR; Tap WD; D'Angelo SP; Keohan ML; Van Tine BA; Agulnik M; Horvath LE; Nair JS; Schwartz GK
Ann Oncol; 2016 Oct; 27(10):1855-60. PubMed ID: 27502708
[TBL] [Abstract][Full Text] [Related]
15. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
Falchook GS; Zhou X; Venkatakrishnan K; Kurzrock R; Mahalingam D; Goldman JW; Jung J; Ullmann CD; Milch C; Rosen LS; Sarantopoulos J
Drugs R D; 2016 Mar; 16(1):45-52. PubMed ID: 26689566
[TBL] [Abstract][Full Text] [Related]
16. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
Falchook G; Kurzrock R; Gouw L; Hong D; McGregor KA; Zhou X; Shi H; Fingert H; Sharma S
Invest New Drugs; 2014 Dec; 32(6):1181-7. PubMed ID: 24879333
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.
Haddad TC; D'Assoro A; Suman V; Opyrchal M; Peethambaram P; Liu MC; Goetz MP; Ingle JN
Breast Cancer Res Treat; 2018 Apr; 168(3):639-647. PubMed ID: 29289986
[TBL] [Abstract][Full Text] [Related]
18. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
[TBL] [Abstract][Full Text] [Related]
20. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
